Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.23 Million EUR | -39.95% |
| 2022 | 12.05 Million EUR | -28.63% |
| 2021 | 16.88 Million EUR | -3.32% |
| 2020 | 17.47 Million EUR | 13.67% |
| 2019 | 15.36 Million EUR | -18.46% |
| 2018 | 18.84 Million EUR | -7.49% |
| 2017 | 20.37 Million EUR | 607.31% |
| 2016 | 2.88 Million EUR | 5.67% |
| 2015 | 2.72 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 4.26 Million EUR | 0.0% |
| 2023 Q2 | 7.97 Million EUR | 0.0% |
| 2023 Q4 | 7.23 Million EUR | 0.0% |
| 2023 FY | 7.23 Million EUR | -39.95% |
| 2022 Q2 | 15.69 Million EUR | 0.0% |
| 2022 FY | 12.05 Million EUR | -28.63% |
| 2022 Q4 | 12.05 Million EUR | 0.0% |
| 2021 Q2 | 19.16 Million EUR | 0.0% |
| 2021 FY | 16.88 Million EUR | -3.32% |
| 2021 Q4 | 16.88 Million EUR | 0.0% |
| 2020 Q2 | 15.28 Million EUR | 0.0% |
| 2020 Q4 | 17.47 Million EUR | 0.0% |
| 2020 FY | 17.47 Million EUR | 13.67% |
| 2019 FY | 15.36 Million EUR | -18.46% |
| 2019 Q4 | 15.36 Million EUR | 0.0% |
| 2019 Q2 | 16.39 Million EUR | 0.0% |
| 2018 Q2 | 17.96 Million EUR | 0.0% |
| 2018 Q4 | 18.84 Million EUR | 0.0% |
| 2018 FY | 18.84 Million EUR | -7.49% |
| 2017 Q2 | 2.23 Million EUR | 0.0% |
| 2017 FY | 20.37 Million EUR | 607.31% |
| 2017 Q4 | 20.37 Million EUR | 0.0% |
| 2016 Q4 | 2.88 Million EUR | 0.0% |
| 2016 FY | 2.88 Million EUR | 5.67% |
| 2015 FY | 2.72 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 50.797% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 97.787% |
| Adocia SA | 24.95 Million EUR | 70.998% |
| Aelis Farma SA | 26.28 Million EUR | 72.46% |
| Biophytis S.A. | 11.93 Million EUR | 39.362% |
| Advicenne S.A. | 12.4 Million EUR | 41.664% |
| genOway Société anonyme | 31.84 Million EUR | 77.27% |
| IntegraGen SA | 8 Million EUR | 9.532% |
| Medesis Pharma S.A. | 1.92 Million EUR | -275.726% |
| Neovacs S.A. | 47.53 Million EUR | 84.773% |
| NFL Biosciences SA | 3.97 Million EUR | -82.282% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 51.467% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -93.173% |
| Sensorion SA | 46.49 Million EUR | 84.433% |
| TME Pharma N.V. | 2.49 Million EUR | -190.555% |
| Valbiotis SA | 33.24 Million EUR | 78.231% |
| TheraVet SA | 7.53 Million EUR | 3.935% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 79.481% |
| argenx SE | 4.11 Billion EUR | 99.824% |
| BioSenic S.A. | 9.55 Million EUR | 24.284% |
| Celyad Oncology SA | 16.28 Million EUR | 55.548% |
| DBV Technologies S.A. | 165.65 Million USD | 95.631% |
| Galapagos NV | 4.35 Billion EUR | 99.834% |
| Genfit S.A. | 173.87 Million EUR | 95.837% |
| GeNeuro SA | 6.31 Million EUR | -14.65% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 84.821% |
| Innate Pharma S.A. | 184.19 Million EUR | 96.071% |
| Inventiva S.A. | 69.13 Million EUR | 89.532% |
| MaaT Pharma SA | 42.93 Million EUR | 83.141% |
| MedinCell S.A. | 36.94 Million EUR | 80.411% |
| Nanobiotix S.A. | 93.89 Million EUR | 92.292% |
| Onward Medical N.V. | 43.62 Million EUR | 83.411% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 93.229% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 91.163% |
| Oxurion NV | 6.55 Million EUR | -10.5% |
| Pharming Group N.V. | 426.33 Million EUR | 98.302% |
| Poxel S.A. | 4.82 Million EUR | -50.067% |
| GenSight Biologics S.A. | 9.08 Million EUR | 20.351% |
| Transgene SA | 45.21 Million EUR | 83.993% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.623% |
| UCB SA | 15.53 Billion EUR | 99.953% |
| Valneva SE | 469.39 Million EUR | 98.458% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 76.523% |